Exosomal delivery of NF-κB inhibitor delays LPS-induced preterm birth and modulates fetal immune cell profile in mouse models

Accumulation of immune cells and activation of the pro-inflammatory transcription factor NF-kappa B in feto-maternal uterine tissues is a key feature of preterm birth (PTB) pathophysiology. Reduction of the fetal inflammatory response and NF-kappa B activation are key strategies to minimize infection-associated PTB. Therefore, we engineered extracellular vesicles (exosomes) to contain an NF-kappa B inhibitor, termed super-repressor (SR) I kappa B alpha. Treatment with SR exosomes (1 x 10(10 )per intraperitoneal injection) after lipopolysaccharide (LPS) challenge on gestation day 15 (E15) prolonged gestation by over 24 hours (PTB <= E18.5) and reduced maternal inflammation (n >= 4). Furthermore, using a transgenic model in which fetal tissues express the red fluorescent protein tdTomato while maternal tissues do not, we report that LPS-induced PTB in mice is associated with influx of fetal innate immune cells, not maternal, into feto-maternal uterine tissues. SR packaged in exosomes provides a stable and specific intervention for reducing the inflammatory response associated with PTB.

Automated summary

Packaging NF-kappa B inhibitor SR in exosomes provides a stable and specific intervention for reducing inflammatory response associated with PTB, prolonging gestation and reducing maternal inflammation. In a mouse model, LPS-induced PTB is associated with influx of fetal innate immune cells into feto-maternal uterine tissues.